From Diagnosis to Drug Development

from Moving Medicine Forward · host CTI Clinical Trials

Chuck Scheper, Board Chair at Bexion Pharmaceuticals, shares how a stage IV non-Hodgkin lymphoma diagnosis at age 39 and a life-saving clinical trial led to his lifelong commitment to cancer research. He joins Tim Schroeder, CEO and Chairman of CTI, to discuss the founding of VaxCella, the evolution of cancer therapies, the importance of patient-centered research, and the role of collaboration in advancing drug development, highlighting resilience, innovation, and the impact of clinical trials.

Episode metadata supplied by the publisher feed · Published Oct 16, 2025

Embed this episode

Attribution link and audio player

NOW PLAYING

From Diagnosis to Drug Development

0:00 17:01

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Moving Medicine Forward?

This episode is 17 minutes long.

When was this Moving Medicine Forward episode published?

This episode was published on October 16, 2025.

Can I download this Moving Medicine Forward episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!